Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes.
Publication
, Journal Article
Swords, RT; Watts, J; Erba, HP; Altman, JK; Maris, M; Anwer, F; Hua, Z; Stein, H; Faessel, H; Sedarati, F; Dezube, BJ; Giles, FJ ...
Published in: Blood Cancer J
February 3, 2017
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Blood Cancer J
DOI
EISSN
2044-5385
Publication Date
February 3, 2017
Volume
7
Issue
2
Start / End Page
e520
Location
United States
Related Subject Headings
- Young Adult
- Pyrimidines
- NEDD8 Protein
- Myelodysplastic Syndromes
- Middle Aged
- Maximum Tolerated Dose
- Male
- Leukemia, Myeloid, Acute
- Humans
- Female
Citation
APA
Chicago
ICMJE
MLA
NLM
Swords, R. T., Watts, J., Erba, H. P., Altman, J. K., Maris, M., Anwer, F., … DeAngelo, D. J. (2017). Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes. Blood Cancer J, 7(2), e520. https://doi.org/10.1038/bcj.2017.1
Swords, R. T., J. Watts, H. P. Erba, J. K. Altman, M. Maris, F. Anwer, Z. Hua, et al. “Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes.” Blood Cancer J 7, no. 2 (February 3, 2017): e520. https://doi.org/10.1038/bcj.2017.1.
Swords RT, Watts J, Erba HP, Altman JK, Maris M, Anwer F, et al. Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes. Blood Cancer J. 2017 Feb 3;7(2):e520.
Swords, R. T., et al. “Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes.” Blood Cancer J, vol. 7, no. 2, Feb. 2017, p. e520. Pubmed, doi:10.1038/bcj.2017.1.
Swords RT, Watts J, Erba HP, Altman JK, Maris M, Anwer F, Hua Z, Stein H, Faessel H, Sedarati F, Dezube BJ, Giles FJ, Medeiros BC, DeAngelo DJ. Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes. Blood Cancer J. 2017 Feb 3;7(2):e520.
Published In
Blood Cancer J
DOI
EISSN
2044-5385
Publication Date
February 3, 2017
Volume
7
Issue
2
Start / End Page
e520
Location
United States
Related Subject Headings
- Young Adult
- Pyrimidines
- NEDD8 Protein
- Myelodysplastic Syndromes
- Middle Aged
- Maximum Tolerated Dose
- Male
- Leukemia, Myeloid, Acute
- Humans
- Female